Xtandi seeks first-line status

Share this article:

The FDA gave Medivation and Astellas a boost by giving priority review to the partners' application to expand the prostate cancer drug's indication to include first-line status.

The drug is currently indicated for metastatic castration-resistant prostate cancer patients who have previously undergone chemotherapy and was approved in 2012.

PM Live notes that a pre-chemo indication will allow Medivation to provide early treatment competition for Janssen's prostate cancer drug Zytiga, which lassoed the pre-chemo approval in July 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.